Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
A Japanese health ministry panel on April 18 recommended approval for Ferring Pharmaceuticals’ bladder cancer gene therapy and Fujifilm Toyama Chemical’s autologous stem cell therapy for meniscus injuries. The Pharmaceutical Affairs Council’s Committee on Regenerative Medicine Products, Biological Products and…
To read the full story
Related Article
- Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
- Fujifilm Bags Japan Approval for Meniscus Regenerative Therapy
May 11, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
- Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus
November 27, 2025
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
- Fujifilm Seeks Japan Nod for Stem Cell Therapy for Meniscus Injuries
May 15, 2025
REGULATORY
- Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
- Japan Enacts Reform Bill Paving Way for OTC-Like Drug Charges
June 1, 2026
- Four Pharma Secondees Join AMED Drug Discovery Initiative
June 1, 2026
- Finance Minister Backs Further Debate on Low-Risk Medicines: CEFP Minutes
May 29, 2026
- LDP HQ Finalizes Recommendations ahead of Growth Strategy
May 29, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…